TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05097612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Placebo LiftSuit Exoskeleton
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). In this condition the EES are removed from the device to create a placebo device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiftSuit Exoskeleton (low support level)
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiftSuit Exoskeleton (medium support level)
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiftSuit Exoskeleton (high support level)
Description: The LiftSuit is a soft passive wearable device that is designed to support the hip and back muscles during forward leaning and lifting. It exerts it function through Elastic Energy Storages (EES). EES of different three different levels of stiffness (low, medium, high stiffness) will be used.
Study: NCT05465941

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood and stool sample collection
Study: NCT05237219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Passive heating
Description: Patients will perform baths in 38°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoneutral
Description: Patients will perform baths in 30-32°C natural thermal mineral water a maximum of five times per week, over a 12-week period. This will result in a maximum of 60 visits. Each visit will take a maximum of 30 minutes with a physical check-up before and after the bath.
Study: NCT05036590

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: The control group consisted of caregivers included during the control period, before the intervention was deployed, i.e., before the BREF program was implemented by the centers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: The intervention group consists of caregivers included during the intervention period. Caregivers in the intervention group will benefit from the BREF program.
Study: NCT06645431

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Water Intake
Description: Previous studies have not observed blood glucose with adequate vs. low water intake in a free-living situation. The use of continuous glucose monitors allows this.
Study: NCT06191445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Landmark Technique
Description: The investigator will perform spinal anesthesia using the conventional landmark technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Assisted Technique
Description: The investigator will perform spinal anesthesia using the ultrasound assisted technique.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Real-Time Ultrasound Guided Technique
Description: The investigator will perform spinal anesthesia using the real-time ultrasound-guided technique.
Study: NCT06263101

Intervention type: OTHER
Intervention: Biochemical testing of abdominal drainage fluid
Description: Drainage fluid was collected from patients on the first and third postoperative days to test the levels of three biochemical tests (albumin, lactate dehydrogenase \[LDH\], adenosine deaminase \[ADA\]).

Intervention type: OTHER
Intervention: Cytological examination of abdominal drainage fluid
Description: Cytological examination of abdominal drainage fluid on the first postoperative day and the third postoperative day, calculation of neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), prognostic nutritional index (PNI)

Intervention type: OTHER
Intervention: Peripheral blood cytology tests
Description: Peripheral blood cytology tests on the first postoperative day and the third postoperative day, calculation of Neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio (LMR), platelet lymphocyte ratio (PLR), systemic immunoinflammatory index (SII)
Study: NCT05961527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: Initial dose of 120 mg MDMA HCL and optional supplemental dose of 60 mg MDMA HCL at 1.5 to 2 hours after first dose

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Therapy
Description: Standardized group psychotherapy performed by therapist team in combination with non-directive MDMA therapy
Study: NCT04765982

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Checking diabetes development in follow up at 3 month
Description: An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Checking diabetes development in follow up at 3 month
Description: An outpatient visit will be planned approximately three months after ICU discharge. At the time of this visit, we will obtain age, BMI, waist circumference, diet, exercise, history of hypertension and family and personal history of elevated blood glucose to calculate the Finnish diabetes risk score (FINDRISC) questionnaire. (28) Oral glucose tolerance test (OGTT) will be performed according to the guidelines of the World Health Organization (WHO) with 75-g glucose load. Diabetes will be diagnosed according to the American Diabetes Association guidelines that stat fasting plasma glucose ≥126 mg/dl(7mmol/L) and/or 2-h plasma glucose during the OGTT ≥200 mg/dl (11.1mmol/L) and/or HbA1c ≥6.5 % (48 mmol/L); impaired glucose tolerance is noted when 2-h plasma glucose during the OGTT is between 140-200 mg/dl (7.7-11.1mmol/L). Impaired fasting glucose defined as fasting plasma glucose between 100-126 mg/dl (55.7mmol/L). (29)
Study: NCT04861610

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief mindfulness based program
Description: An intervention promotes the acceptance and emotion regulation in caregiving for frail older adults

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation
Description: An intervention promotes the coping and problem solving in caregiving for the frail older adults
Study: NCT05924334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: reiki
Description: Processing steps of Reiki application; During the Reiki process, the practitioner will keep the hands just above the recipient. It will be explained to the individual that he may feel the feeling of temperature, tingling, drowsiness, refreshment or healing during therapy.~During the application, the person does not need to be in a lying position or remove their clothes. It is enough to remove the jewelry on it.~In order to ensure the flow of energy during the application, the arms and legs of the individual should stand open on both sides of the body, and the hands and feet will not be crossed in order not to disrupt the flow of energy.~The practitioner will pass the right side of the individual and correct the energy existing around the body with the right hand to the feet and from top to bottom by correcting the energy field of the individual.~The application time will be between 20 and 30 minutes on average.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study: NCT06109324

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation of the upper limb
Description: Upper limb rehabilitation using a set of 4 devices. A set of motor/cognitive exercises will be selected to train also attention, memory, executive function, speed of processing, and visuospatial abilities.The following devices will be used: (a) a robotic device that allows passive, active, and active-assistive planar movements of the shoulder and elbow joints (Motore, Humanware); (b) a robotic device that allows passive, active, and active-assistive finger flexion and extension movements (Amadeo, Tyromotion); (c) a sensor-based system that allows unsupported 3-dimensional movements of shoulder, elbow, and wrist joint, both unimanual and bimanual (Pablo, Tyromotion); and (d) a robotic system that allows 3-dimensional, unimanual and bimanual, movements of the shoulder joint, with arm weight support (Diego, Tyromotion).~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation of the upper limb
Description: Upper limb rehabilitation using conventional techniques, focused on upper limb reprogramming sensorimotor function, hypertonus, inhibition and functional improvement.~The rehabilitation treatment will be performed daily for 45 minutes, 5 days/week, for a total of 30 sessions.
Study: NCT04618276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: PDT with two different photosensitizers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: PDT with two different photosensitizers
Study: NCT05540860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 1
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 2
Description: Sevasemten is administered orally once per day
Study: NCT05012176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Participate in EFT

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Participate in ERT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04965727

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Device implantation
Description: The intervention involves the insertion of lead electrodes (Medtronic SenSight Directional Lead) in the right and left lateral hypothalamus through craniotomy and an implantable pulse generator (Medtronic Model B35200 Percept™ PC) in the upper part of the pectoralis major (under the clavicle).
Study: NCT02587884

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: Patients will treated by TACE in 4 or 8 weeks after operation.
Study: NCT06416072

Intervention type: RADIATION
Intervention: NAV4694
Description: Amyloid PET imaging with NAV4694 injection
Study: NCT05540860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 2
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 3
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 4
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevasemten Dose 5
Description: Sevasemten is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day
Study: NCT06001372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine, 0.5-1.2mg/kg, administered intramuscularly~* Doses can range 0.5-1.2 mg/kg. Starting dose for all participants will be 0.5mg/kg.~* Dose can be titrated up to maximum of 1.2 mg/kg or titrated down to 0.5 mg/kg based on response and clinical judgement.~* Dose will be administered by injecting into large muscle mass (eg, deltoid, gluteal muscle, thigh)
Study: NCT05540860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered orally once per day
Study: NCT04621188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Description: 100 mg once daily
Study: NCT05963308

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Minds
Description: The group intervention (approximately 5 participants per group, 8 groups) is facilitated by two clinicians and consists of 8 sessions (one per week for 8 weeks), with each session focusing on a specific aspect of the return-to-work process from a cognitive-behavioral perspective:~Week1: Coping with work stress at work W2 and W3: Recognizing and modifying my dysfunctional beliefs linked to work W4: Overcoming obstacles linked to work functioning and maintaining work W5: To put in place needed work accommodations with the support of the immediate supervisor W6: My strengths and competencies related to work W7: Accepting criticism and asserting myself appropriately W7: My strengths and related skills W8: My best coping strategies for work Both intervention and control participants receive their standard individualized care from their clinician. However, for the experimental participants, the Healthy Minds intervention is an added component to their regular care.
Study: NCT05814393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment Period(JW0201)
Description: JW0201: 200mg/day For 24 weeks(PO, BID) C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment Period(Placebo)
Description: C2022: ≥1,000 mg/day for 24 Weeks(PO, BID) C2203: 25 mg/day for 24 Weeks(PO, BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Extension Period(JW0201)
Description: JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extension Period(JW0201)
Description: JW0201: 200mg/day For 28 weeks(PO, BID) C2022: ≥1,000 mg/day for 28 Weeks(PO, BID) C2203: 25 mg/day for 28 Weeks(PO, BID)
Study: NCT05270486

Intervention type: PROCEDURE
Intervention: Electromagnetic navigation system
Description: The aim of this study is to assess the safety and efficacy of TELD assisted by electromagnetic navigation for treating lumbar disc herniation (LDH).
Study: NCT05365035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine
Description: Given by Vein (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given under the skin; subcutaneous injection (SQ)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by IV or subcutaneous injection (SQ)
Study: NCT06026631

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Lipidomic analysis for breast cancer patients
Description: Lipidomic analysis for breast cancer patients
Study: NCT04824911

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300mg loading and 75mg/day from day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300mg loading and 75mg/day from day 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin(100-300mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin(100-300mg/day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 40-80mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20 mg/day.
Study: NCT04877366

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: Sprinkled Format REDUCOSE.
Description: 2 G powder sprinkle containing 250 mg REDUCOSE (mulberry leaf extract - 250 mg - 5% DNJ) + fiber, vitamin D, and chromium picolinate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference control
Description: A placebo matching to the test product will be used as control

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Active comparator
Description: Acarbose 100 mg tablet (provided in open-label format)
Study: NCT05556616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modakafusp alfa
Description: Modakafusp alfa intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib injection subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab injection subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules orally.
Study: NCT05066997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone ophthalmic suspension (OCS-01)
Description: The interventional drug OCS-01 eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Stage 1: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Subjects will be dosed with eye drop of OCS-01 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: The vehicle drug (placebo) eye drops will be dispensed in single dose containers for each subject to have enough medication until the next visit.~Stage 1: Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 6 weeks (maintenance phase).~Stage 2: Subjects will be dosed with eye drop of vehicle 6 times per day for 6 weeks (induction phase) followed by 3 times per day for 46 weeks (maintenance phase).
Study: NCT04925388

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid molecular diagnosis
Description: peritoneal samples will be analysed using Unyvero IAI test

Intervention type: OTHER
Group type: OTHER
Intervention: conventional method analysis
Description: peritoneal samples will be analysed using conventional method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional method analysis
Description: peritoneal samples will be analysed using conventional method
Study: NCT06472726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IONA Mind app
Description: The IONA Mind app is a smartphone app that delivers mental health support.
Study: NCT05547438

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NTS-104 TRIS
Description: Subjects will receive a single IV infusion of either 0.8, 4, 8, or 16 mg/mL NTS-104 depending on the Cohort number
Study: NCT05727436

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dentoblis
Description: Dissolve the tablets in the mouth once a day for 4 weeks
Study: NCT05547438

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered an IV infusion of placebo and the same duration and volume as the subjects administered NTS-104 TRIS in the cohort
Study: NCT05118386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RSM01
Description: Cohort 1: RSM01 300 mg IV~Cohort 2: RSM01 300 mg IM~Cohort 3: RSM01 1000 mg IV~Cohort 4: RSM01 3000 mg IV~Cohort 5: RSM01 600 mg IM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort 1: Placebo IV~Cohort 2: Placebo IM~Cohort 3: Placebo IV~Cohort 4: Placebo IV~Cohort 5: Placebo IM
Study: NCT06026631

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lipidomic analysis for breast cancer patients
Description: Lipidomic analysis for breast cancer patients
Study: NCT04878185

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Preoperative exercise
Study: NCT04705766

Intervention type: OTHER
Intervention: Urine Collection
Description: A urine collection kit will be mailed to subjects' residence at 3 different timepoints over the course of 1 year to be returned to study team, upon which KIT score and other biomarkers will be assessed as outlined in the study design.